XOMA Royalty Corp (XOMA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, XOMA Royalty Corp's filing signal turned positive.

XOMA Royalty Corporation operates as a royalty aggregator, providing capital to biotechnology companies in exchange for economic rights to future milestone and royalty payments. The company aims to generate stockholder value through a diversified portfolio of over 120 commercial products and pre-commercial therapeutic candidates, mitigating single-asset risk with a capital-efficient, low-cost structure. Since transforming its business model in 2017, XOMA has expanded its portfolio by acquiring rights to future milestones and royalties, currently anchored by seven commercial-stage assets. In 2025, the company received $33.6 million in commercial payments and $16.9 million from milestone payments, totaling $50.5 million in cash receipts. Its strategy focuses on acquiring early to mid-stage clinical assets licensed to well-funded sponsors with established expertise, as well as late-stage and commercial assets addressing unmet medical needs.

Revenue is primarily driven by milestone payments and royalties received from acquired economic rights to future payments associated with pharmaceutical products. The company also recognizes income from purchased receivables under the effective interest rate (EIR) method and the cost recovery method.